Bayer AG and Johnson & Johnson have agreed to jointly settle $775 million in lawsuits over their Xarelto (rivaroxaban) blood thinner.
More than 25,000 plaintiffs have accused the drug makers of failing to warn of the bleeding risks associated with Xarelto and believe that their injuries could have been prevented with adequate information.
Trending: Pharmacy Education For The 21st Century
Injuries cited in the cases include the development of uncontrollable and irreversible bleeding, which has led to severe injuries and deaths. Anticoagulants as a category were linked with about 3,000 deaths in 2016, according to the Institute for Safe Medication Practices.
Xarelto has proven to be Bayer’s best-selling drug, earning $4.07 billion (€3.6 billion). J&J reported $2.47 billion earned from the drug.